09/20/12 — Plaintiff Suzannah Marek has recently filed a Yaz Lawsuit against multiple Defendants for damages associated with her ingestion of the pharmaceutical drug Yasmin (ethinyl estradiol and drospirenone), which is an oral contraceptive designed, manufactured, supplied, marketed, and distributed by the named Defendants in her Complaint. Specifically, Plaintiff alleges that as a direct result of her use of Yasmin, Plaintiff Suzannah Marek was diagnosed with a pulmonary embolism on March 5, 2003. We have not been informed at this time whether or not this case will be added to the Yaz Multi District Litigation, which is often referred to as the Yaz Class Action Lawsuit.
The Yasmin Lawsuit as well as the Yaz Lawsuit are both based on nearly idenfical causes of action. Yasmin and Yaz contain the same estrogen component, ethinyl estradiol, which has been used in the lower dose birth control pills for decades. However, its other component, drospirenone, is a new type of progestin and is considered a “fourth generation” progestin. Plaintiff alleges that no other birth control pills contain drospirenone, except for a recently approved generic version of Yasmin marketed under the trade name Ocella and the generic version of Yaz that is marketed under the trade name Gianvi (which The Associated Press and Reuters reported was approved by the FDA in June 2010). Plaintiff further alleges that Drospirenone is new and there are not decades of data available to support its safe use. Studies that were done prior to FDA approval, however, indicate that drospirenone has certain effects that are different from traditional second generation progestins, and is potentially more dangerous.
Plaintiff asserts that one possible mechanism of action is that drospirenone interacts differently with ethinyl estradiol in comparison to other progestins, such that it does not sufficiently counterbalance the clotting effects of estrogen as do other progestins (particularly the second generation progestins). Plaintiff states that another possible mechanism of action is that drospirenone causes an increase in potassium levels in the blood, which can lead to a condition known as hyperkalemia if the potassium levels become too high. Hyperkalemia can cause rhythm disturbances, such as extrasystolies, pauses, or bradycardia. If left untreated. If hyperkalemia disrupts the normal heart rhythms, the flow of blood through the heart can be slowed to the point that it permits blood clots to form. Blood clots in the heart can then lead to heart attacks, or the clots can break off and travel to the lungs where they can cause pulmonary embolism, or can travel to the brain causing stroke.
For more information on the Yaz Lawsuit or the Yasmin Lawsuit or to arrange a free legal consultation with a Yaz Lawyer about your potential Yaz Lawsuit , contact the toll free Yaz Lawsuit Hotline at (800)611-7080.